Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: A randomized, double-blind, placebo-controlled, pilot study in healthy volunteers

Nutrition Journal

Volumn 9, Issue 1, 2010, Pages

  Udani, Jay K ^a,b   Singh, Betsy B ^a   Barrett, Marilyn L ^c   Singh, Vijay J ^a  

^a Medicus Research LLC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pharmacognosy Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOGALACTAN; CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; PNEUMOCOCCUS VACCINE; RESISTAID; UNCLASSIFIED DRUG; GALACTAN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SCORING SYSTEM; SCREENING TEST; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; ANTIBODY PRODUCTION; BLOOD; IMMUNOLOGY; MIDDLE AGED;

LARIX; STREPTOCOCCUS PNEUMONIAE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; GALACTANS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 77956892631     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-9-32     Document Type: Article

References (20)

1. Humoral immune defense (antibodies): recent advances. HL Twigg III, Proc Am Thorac Soc 2005 2 417 421 10.1513/pats.200508-089JS 16322592
2. Markers to measure immunomodulation in human nutrition intervention studies. R Albers JM Antoine R Bourdet-Sicard PC Calder M Gleeson B Lesourd S Samartín IR Sanderson J Van Loo FW Vas Dias B Watzl, Br J Nutr 2005 94 452 481 10.1079/BJN20051469 16176618
3. Pneumococcal vaccination in adults: recommendations, trends, and prospects. PV Targonski GA Poland, Cleve Clin J Med 2007 74 401 10 413 10.3949/ccjm.74.6.401 17569198
4. Pneumococcal vaccination and revaccination of older adults. AS Artz WB Ershler DL Longo, Clin Microbiol Rev 2003 16 308 318 10.1128/CMR.16.2.308-318. 2003 12692100
5. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. SN Meydani M Meydani JB Blumberg LS Leka G Siber R Loszewski C Thompson MC Pedrosa RD Diamond BD Stollar, JAMA 1997 277 1380 1386 10.1001/jama.277.17.1380 9134944
6. Effects of prebiotics on the immune response to vaccination in the elderly. D Bunout S Hirsch dlM Pia C Munoz F Haschke P Steenhout P Klassen G Barrera V Gattas M Petermann, JPEN J Parenter Enteral Nutr 2002 26 372 376 10.1177/0148607102026006372 12405649
7. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. GS Kelly, Altern Med Rev 1999 4 96 103 10231609
8. Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and D-galactose. J Beuth HL Ko K Oette G Pulverer K Roszkowski G Uhlenbruck, J Cancer Res Clin Oncol 1987 113 51 55 10.1007/BF00389966 3818778
9. Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan. J Beuth HL Ko V Schirrmacher G Uhlenbruck G Pulverer, Clin Exp Metastasis 1988 6 115 120 10.1007/BF01784842 3345610
10. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. M Roxas J Jurenka, Altern Med Rev 2007 12 25 48 17397266
11. Immunomodulatory effects of arabinogalactan-proteins from Baptisia and Echinacea. B Classen S Thude W Blaschek M Wack C Bodinet, Phytomedicine 2006 13 688 694 10.1016/j.phymed.2005.10.004 17085292
12. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. B Luettig C Steinmuller GE Gifford H Wagner ML Lohmann-Matthes, J Natl Cancer Inst 1989 81 669 675 10.1093/jnci/81.9.669 2785214 (Pubitemid 19115756)
13. Effect over time of in-vivo administration of the polysaccharide arabinogalactan on immune and hemopoietic cell lineages in murine spleen and bone marrow. NL Currier D Lejtenyi SC Miller, Phytomedicine 2003 10 145 153 10.1078/094471103321659852 12725568
14. Larch Arabinogalactan is a Novel Immune Modulator. P D'Adamo, J Naturopath Med 1996 4 32 39
15. Oral administration of arabinogalactan affects immune status and fecal microbial populations in dogs. CM Grieshop EA Flickinger GC Fahey Jr, J Nutr 2002 132 478 482 11880574
16. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. LS Kim RF Waters PM Burkholder, Altern Med Rev 2002 7 138 149 11991793
17. Evaluation of arabinogalactan's effect on human immunity. M Nantz A Painter E Parker C McGill S Percival, FASEB J 2001 15 633
18. Effects of larch arabinogalactan on human peripheral blood mononuclear cells: results from in vivo and in vitro human trials. J Causey R Robinson J Feirtag R Fulcher J Slavin, FASEB J 1999 13 589
19. Interindividual variations in the efficacy and toxicity of vaccines. C Thomas M Moridani, Toxicology 2009 19837123
20. Overview of the immune response. DD Chaplin, J Allergy Clin Immunol 2010 125 3 23 10.1016/j.jaci.2009.12.980 20176265